Insmed (NASDAQ:INSM) Stock Price Expected to Rise, Mizuho Analyst Says

Insmed (NASDAQ:INSM - Get Free Report) had its price objective increased by analysts at Mizuho from $96.00 to $110.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has an "outperform" rating on the biopharmaceutical company's stock. Mizuho's price target points to a potential upside of 11.43% from the company's previous close.

Several other analysts also recently issued reports on the company. UBS Group cut their price objective on Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Royal Bank of Canada upped their target price on Insmed from $99.00 to $106.00 and gave the company an "outperform" rating in a report on Wednesday. HC Wainwright upped their target price on Insmed from $90.00 to $120.00 and gave the company a "buy" rating in a report on Wednesday. Bank of America upped their target price on Insmed from $94.00 to $109.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Truist Financial upped their target price on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a report on Friday, February 21st. One analyst has rated the stock with a sell rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, Insmed currently has a consensus rating of "Moderate Buy" and a consensus price target of $104.81.

Insmed Stock Performance

INSM stock traded up $1.84 during trading on Wednesday, hitting $98.72. 2,148,111 shares of the company's stock traded hands, compared to its average volume of 2,165,175. Insmed has a 52 week low of $60.40 and a 52 week high of $100.00. The stock has a market capitalization of $17.98 billion, a price-to-earnings ratio of -17.68 and a beta of 0.80. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The stock has a fifty day moving average price of $70.73 and a two-hundred day moving average price of $73.47.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. During the same period in the previous year, the company earned ($1.06) EPS. The business's revenue for the quarter was up 22.9% compared to the same quarter last year. As a group, equities analysts anticipate that Insmed will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, insider Martina M.D. Flammer sold 9,925 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $65.47, for a total transaction of $649,789.75. Following the transaction, the insider now directly owns 86,596 shares of the company's stock, valued at approximately $5,669,440.12. The trade was a 10.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Sara Bonstein sold 57,766 shares of the business's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $89.12, for a total value of $5,148,105.92. Following the completion of the sale, the chief financial officer now owns 103,412 shares of the company's stock, valued at $9,216,077.44. This trade represents a 35.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 319,932 shares of company stock worth $25,733,693. Corporate insiders own 3.00% of the company's stock.

Institutional Trading of Insmed

Institutional investors have recently modified their holdings of the stock. Cullen Frost Bankers Inc. lifted its position in shares of Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 221 shares during the period. Elequin Capital LP bought a new stake in shares of Insmed during the 4th quarter worth $28,000. Steward Partners Investment Advisory LLC lifted its position in shares of Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 163 shares during the last quarter. V Square Quantitative Management LLC lifted its position in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 248 shares during the last quarter. Finally, NBC Securities Inc. bought a new stake in shares of Insmed during the 1st quarter worth $49,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.